Gilead Sciences Inc
NASDAQ: GILD
$88.08
-$0.68 (-0.8%)
Closing Price on October 29, 2024
GILD Articles
The February 28 short interest data have been compared with the previous report, and short interest moves in the selected biotech stocks were mixed.
Published:
Last Updated:
These five top companies with different health care businesses all can provide nice exposure to the sector in growth portfolios. All are rated Buy at Jefferies and make sense now.
Published:
Last Updated:
The short interest data are out for the most recent settlement date, February 15. Generally speaking, companies within the biotech industry are considered to be a riskier group of stocks, with big...
Published:
Last Updated:
Cancer immunotherapy approaches have attracted the attention of Big Pharma in the past. New technology from Stanford University probably will be no exception if Phase 1 results are positive.
Published:
Last Updated:
If the collaboration between Sangamo and Kite Pharma works out, some investors might just ask why Gilead did not just acquire Sangamo.
Published:
Last Updated:
Sangamo Therapeutics saw its shares make a solid gain on Thursday after the company announced that it had entered into a worldwide partnership with a subsidiary of Gilead Sciences.
Published:
Last Updated:
With indiscriminate selling absolutely punishing some of the top large cap biotech stocks, one analyst says now is the time to buy.
Published:
Last Updated:
The January 31 short interest data have been compared with the previous report, and short interest in most of the selected biotech stocks increased.
Published:
Last Updated:
The top analyst upgrades, downgrades and other research calls from Thursday include Apple, GE, Gilead, Humana, Oasis Petroleum, Sprint, Wynn, Yelp and Zynga.
Published:
Last Updated:
24/7 Wall St. has put together a preview of Disney, General Motors, Twitter and other major companies scheduled to report their quarterly results this week.
Published:
Last Updated:
24/7 Wall St. has included a calendar of a some of the biggest companies expecting clinical trial and U.S. Food and Drug Administration (FDA) updates in February.
Published:
Last Updated:
The top analyst upgrades, downgrades and other research calls from Tuesday include Abbott Labs, Alphabet, Amazon.com, General Electric, Gilead Sciences, Intel, Seagate Technology and U.S. Steel.
Published:
Last Updated:
Monday was a down day for the U.S. markets. Although the markets have been pushing new highs recently, today was not one of those days. Crude oil started the week out on a negative note, pulling back...
Published:
Last Updated:
Johnson &; Johnson, Gilead Sciences and Amicus Therapeutics are among companies expecting clinical trial and FDA updates in February.
Published:
Last Updated:
The top analyst upgrades, downgrades and other research calls from Friday include Bed Bath & Beyond, Caterpillar, FirstEnergy, Gilead Sciences, Intel, Starbucks and Yamana Gold.
Published: